Skip to content

Zevra Therapeutics, Inc. ZVRA License — Contract with customer, liability

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNLicense — Contract Liabilities
$90M
Nuvation Bio logo
NUVBLicense — Deferred Revenue
$58.7M
Winmark logo
WINASoftware License Fees — Deferred Revenue
$1.9M0.0%
Anterix logo
ATEXLicense — Payments remaining
$7.7M
Praxis Precision Medicines, Inc. logo
PRAXLicense — Contract with customer, liability, revenue recognized
$0
Porch Group, Inc. logo
PRCHSoftware & Data — Contract with Customer, Liability
$2.11M-38.1%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s license — contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s license — contract with customer, liability?
Zevra Therapeutics, Inc. (ZVRA) reported license — contract with customer, liability of $0 in Q1 2026.
What does license — contract with customer, liability mean?
This metric reflects the balance of payments received from customers for which the company has not yet satisfied its performance obligations under a licensing agreement. It represents a future obligation to provide goods or services, often referred to as deferred revenue.